BACKGROUND: Cost-effectiveness analysis of MammaPrint(®) (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. METHODS: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online(®) (online algorithm), 70-gene signature or Oncotype DX(®) (21-gene assay). RESULTS: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was €7100, €6380 and €4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost-effective from year 7 versus online algorithm (lifetime: €1457 per quality-adjusted life years gained). CONCLUSIONS: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost-effective versus online algorithm.
BACKGROUND: Cost-effectiveness analysis of MammaPrint(®) (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. METHODS: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online(®) (online algorithm), 70-gene signature or Oncotype DX(®) (21-gene assay). RESULTS: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 and 0.75, respectively, with 70-gene signature. At year 5, the mean cost of 21-gene assay, 70-gene signature and online algorithm was €7100, €6380 and €4580, respectively. 70-gene signature was dominant versus 21-gene assay at any time horizon and would be cost-effective from year 7 versus online algorithm (lifetime: €1457 per quality-adjusted life years gained). CONCLUSIONS: 70-gene signature was a dominant strategy over 21-gene assay and was highly cost-effective versus online algorithm.
Entities:
Keywords:
MammaPrint®; Oncotype DX®; breast cancer; cost–effectiveness; diagnosis; genotyping
Authors: R Colomer; I Aranda-López; J Albanell; T García-Caballero; E Ciruelos; M Á López-García; J Cortés; F Rojo; M Martín; J Palacios-Calvo Journal: Clin Transl Oncol Date: 2017-12-22 Impact factor: 3.405
Authors: Ramona Erber; Miriam Angeloni; Robert Stöhr; Michael P Lux; Daniel Ulbrich-Gebauer; Enrico Pelz; Agnes Bankfalvi; Kurt W Schmid; Robert F H Walter; Martina Vetter; Christoph Thomssen; Doris Mayr; Frederick Klauschen; Peter Sinn; Karl Sotlar; Katharina Stering; Albrecht Stenzinger; Marius Wunderle; Peter A Fasching; Matthias W Beckmann; Oliver Hoffmann; Rainer Kimmig; Nadia Harbeck; Rachel Wuerstlein; Fulvia Ferrazzi; Arndt Hartmann Journal: Int J Mol Sci Date: 2022-08-05 Impact factor: 6.208